In situ synthesis of MnO 2 micro/nano-adjuvants for enhanced immunotherapy of breast tumors

Kun Chen,Huimin Lin,Xin Peng,Ziying Wu,Jingyue Dai,Yi Sun,Yaxuan Feng,Ziyi Huang,Zhiqiang Yu,Meng Yu,Guangyu Yao,Jigang Wang

DOI: https://doi.org/10.1016/j.cclet.2024.110045

IF: 9.1

2024-05-27

Chinese Chemical Letters

Abstract:This study presents an approach to enhanced cancer immunotherapy through the in situ synthesis of potassium permanganate (KMnO 4 ) derived manganese dioxide (MnO 2 ) micro/nano-adjuvants. Addressing the limitations of traditional immunotherapy due to patient variability and the complexity of the tumor microenvironment, our research establishes KMnO 4 as a potent immunomodulator that enhances the efficacy of anti-programmed death-ligand 1 ( α PD-L1) antibodies. The in situ synthesized MnO 2 adjuvants in the tumor exhibit direct interactions with biological systems, leading to the reduction of MnO 2 to Mn 2+ within the tumor, and thereby improving the microenvironment for immune cell activity. Our in vitro and in vivo models demonstrate KMnO 4 's capability to induce concentration-dependent cytotoxicity in tumor cells, triggering DNA damage and apoptosis. It also potentiates immunogenic cell death by upregulating calreticulin and high mobility group box 1 (HMGB1) on the cell surface. The combination of KMnO 4 with α PD-L1 antibodies substantially inhibits tumor growth, promotes dendritic cell maturation, and enhances CD8 + T cell infiltration, resulting in a significant phenotypic shift in tumor-associated macrophages towards a pro-inflammatory M1 profile. Our findings advocate for further research into the long-term efficacy of KMnO 4 and its application in diverse tumor models, emphasizing its potential to redefine immune checkpoint blockade therapy and offering a new vista in the fight against cancer.

chemistry, multidisciplinary